These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 17056125)

  • 1. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.
    Tüzün E; Saini SS; Morgan BP; Christadoss P
    J Neuroimmunol; 2006 Dec; 181(1-2):29-33. PubMed ID: 17056125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis.
    Li J; Tüzün E; Wu XR; Qi HB; Allman W; Saini SS; Christadoss P
    J Neuroimmunol; 2008 Feb; 194(1-2):44-53. PubMed ID: 18207575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ICOS is essential for the development of experimental autoimmune myasthenia gravis.
    Scott BG; Yang H; Tüzün E; Dong C; Flavell RA; Christadoss P
    J Neuroimmunol; 2004 Aug; 153(1-2):16-25. PubMed ID: 15265659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.
    Tüzün E; Scott BG; Goluszko E; Higgs S; Christadoss P
    J Immunol; 2003 Oct; 171(7):3847-54. PubMed ID: 14500686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia.
    Kaminski HJ; Kusner LL; Richmonds C; Medof ME; Lin F
    Exp Neurol; 2006 Dec; 202(2):287-93. PubMed ID: 16859686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis.
    Tüzün E; Saini SS; Yang H; Alagappan D; Higgs S; Christadoss P
    J Neuroimmunol; 2006 May; 174(1-2):157-67. PubMed ID: 16527362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
    Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
    Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
    Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H
    Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.
    Tüzün E; Allman W; Ulusoy C; Yang H; Christadoss P
    Ann N Y Acad Sci; 2012 Dec; 1274():133-9. PubMed ID: 23252908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The susceptibility of Aire(-/-) mice to experimental myasthenia gravis involves alterations in regulatory T cells.
    Aricha R; Feferman T; Scott HS; Souroujon MC; Berrih-Aknin S; Fuchs S
    J Autoimmun; 2011 Feb; 36(1):16-24. PubMed ID: 21035305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis.
    Christadoss P; Tüzün E; Li J; Saini SS; Yang H
    Ann N Y Acad Sci; 2008; 1132():210-9. PubMed ID: 18567870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.
    Kaminski HJ; Li Z; Richmonds C; Lin F; Medof ME
    Exp Neurol; 2004 Oct; 189(2):333-42. PubMed ID: 15380483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic deficiency of estrogen receptor alpha fails to influence experimental autoimmune myasthenia gravis pathogenesis.
    Qi H; Li J; Allman W; Saini SS; Tüzün E; Wu X; Estes DM; Christadoss P
    J Neuroimmunol; 2011 May; 234(1-2):165-7. PubMed ID: 21481948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
    Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
    Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis.
    Zhang GX; Xiao BG; Bai XF; van der Meide PH; Orn A; Link H
    J Immunol; 1999 Apr; 162(7):3775-81. PubMed ID: 10201893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
    Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
    Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ T and B cells cooperate in the immunoregulation of Experimental Autoimmune Myasthenia Gravis.
    Milani M; Ostlie N; Wu H; Wang W; Conti-Fine BM
    J Neuroimmunol; 2006 Oct; 179(1-2):152-62. PubMed ID: 16945426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-DQ6 transgenic mice resistance to experimental autoimmune myasthenia gravis is linked to reduced acetylcholine receptor-specific IFN-gamma, IL-2 and IL-10 production.
    Poussin MA; Goluszko E; David CS; Franco JU; Christadoss P
    J Autoimmun; 2001 Nov; 17(3):175-80. PubMed ID: 11712854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular myasthenia gravis induced by human acetylcholine receptor ϵ subunit immunization in HLA DR3 transgenic mice.
    Wu X; Tuzun E; Saini SS; Wang J; Li J; Aguilera-Aguirre L; Huda R; Christadoss P
    Immunol Lett; 2015 Dec; 168(2):306-12. PubMed ID: 26493475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
    Xiao BG; Duan RS; Zhu WH; Lu CZ
    Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.